CB5138-1 / CohBar - LARVOL DELTA

CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases (GlobeNewswire) - “CohBar, Inc….today announced the selection of CB5138-3 as its lead candidate for advancement into IND-enabling activities. CB5138-3 is a CB5138 Analog...with potential for treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases….In the therapeutic mouse model of IPF, multiple CB5138 Analogs demonstrated positive effects on all study outcomes, including reduction of fibrosis, inflammation, and collagen deposition….CohBar will move forward with IND-enabling activities for CB5138-3 with the goal of initiating clinical studies in 2022….Company is continuing to evaluate the efficacy of the CB5138 Analogs in models of other fibrotic diseases such as NASH, systemic sclerosis, and kidney fibrosis.”

New molecule • New trial • Preclinical • Idiopathic Pulmonary Fibrosis

CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire) - "Our preclinical programs are also progressing, with recent data for a CB5138 Analog...Our goal is to identify a clinical candidate for our IPF program early in the first quarter of 2021, subject to successful completion of the remaining required studies....Antifibrotic and anti-inflammatory effects were demonstrated for MBT2 (CB5138-1) in vitro in human cells and in vivo in prophylactic and therapeutic preclinical models of IPF."

Preclinical • Idiopathic Pulmonary Fibrosis

CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire) - "CohBar, Inc....today announced it will host a Key Opinion Leader (KOL) webinar on the current treatment landscape in idiopathic pulmonary fibrosis (IPF), the unmet medical need, and positive findings from preclinical studies of its CB5138 Analogs on Friday, November 6 at 2:00pm ET....The call will feature a presentation by KOL Toby Maher, MD...who will discuss the current treatment landscape and unmet medical need in treating patients with IPF. Dr. Maher will be available to answer questions following the formal presentations."

Live event • Preclinical • Idiopathic Pulmonary Fibrosis • Pulmonary Disease • Respiratory Diseases

CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model (GlobeNewswire) - "CohBar, Inc....today announced new preclinical data demonstrating that combination of a CB5138 Analog with nintedanib, the leading standard of care for treatment of Idiopathic Pulmonary Fibrosis (IPF), produced enhanced effects compared to nintedanib alone in mice....'We plan to present the data in an upcoming KOL meeting as we continue to move the program towards final selection of a clinical candidate.'...Compared to nintedanib alone, the combination of CB5138-2 and nintedanib produced greater reductions in Ashcroft lung fibrosis score, inflammation, collagen secretion and deposition, and secretion of key pro-inflammatory cytokines."

Preclinical • Idiopathic Pulmonary Fibrosis

Form 424B5 CohBar, Inc. (Streetinsider.com) - "The following are our future plans and expectations with respect to the advancement of our programs which are subject to, among other risks, our receipt of positive clinical and preclinical results and sufficient project funding....In developing our antifibrosis peptides for IPF and fibrotic diseases program, we expect to select a preclinical candidate by the end of 2020, and complete pre-IND enabling activities and initiate a phase 1 study in 2021, with the goal of initiating a phase 2 study in 2022."

New P1 trial • New P2 trial • Preclinical • Idiopathic Pulmonary Fibrosis

[VIRTUAL] MBT2, a Novel Analog of a Mitochondrially Encoded Peptide, Inhibits Fibrogenesis in Cultured Human Lung Cells and Is Effective in Mouse Models of Idiopathic Pulmonary Fibrosis (IPF) (ATS-I 2020) - "In the therapeutic model MBT2 was administered for 14 days beginning 7 days after bleomycin and compared to oral nintedanib (60 mg/kg/day). MBT2 demonstrated consistent antifibrotic effects in cultured human lung cells and in prophylactic and therapeutic mouse models of IPF. MBT2 represents a novel class of molecules derived from a natural, mitochondrially encoded peptide source, with potential for treatment of IPF."

Late-breaking abstract • Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Respiratory Diseases • CCL2 • TNFA

CohBar Presents New Antifibrotic Data at the American Thoracic Society’s Virtual 2020 Conference (GlobeNewswire) - "CohBar, Inc....announced today that its ePoster featuring new antifibrotic data is now available to registered attendees of the American Thoracic Society’s Virtual 2020 Conference, being held August 5 to 10, 2020....The ePoster also shows new data for additional analogs of CB5138 in the therapeutic mouse model of IPF....The new data are being presented in an ePoster titled: 'MBT2, a Novel Analog of a Mitochondrially Encoded Peptide, Inhibits Fibrogenesis in Cultured Human Lung Cells and is Effective in Mouse Models of Idiopathic Pulmonary Fibrosis (IPF).'"

Preclinical • Idiopathic Pulmonary Fibrosis